Scholarlink

<p>Hyperuricemia is a metabolic disorder associated with an increased risk of gout, chronic kidney disease (CKD), and cardiovascular disease (CVD). The management of hyperuricemia in conditions where urate deposition has already occurred primarily relies on xanthine oxidase inhibitors (XOIs), such as allopurinol and Febuxostat. Febuxostat, a non-purine selective XOI, has demonstrated superior urate-lowering efficacy, particularly in patients with renal impairment. This review provides an in-depth analysis of Febuxostat’s pharmacological properties, clinical efficacy, and safety profile, with a focus on cardiovascular and nephroprotective effects.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comprehensive Review on Febuxostat for Hyperuricemia with Gout: Insights from Current Practice and Clinical Trials

  • 期刊论文

  • 发表日期：

    2025年12月26日

查看全文
  • Claudio Borghi,
  • Federica Piani,
  • Athanasios L. Manolis

摘要

Hyperuricemia is a metabolic disorder associated with an increased risk of gout, chronic kidney disease (CKD), and cardiovascular disease (CVD). The management of hyperuricemia in conditions where urate deposition has already occurred primarily relies on xanthine oxidase inhibitors (XOIs), such as allopurinol and Febuxostat. Febuxostat, a non-purine selective XOI, has demonstrated superior urate-lowering efficacy, particularly in patients with renal impairment. This review provides an in-depth analysis of Febuxostat’s pharmacological properties, clinical efficacy, and safety profile, with a focus on cardiovascular and nephroprotective effects.